Argenx's Vyvgart fails Phase 3 in Sjögren's, shares fall

· Health · Belgium · Netherlands

Argenx reported that its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder. A monitoring board recommended stopping the study for futility, a result that took Wall Street by surprise and removed what analysts had described as a "blockbuster expansion opportunity" for the product. The Belgian-Dutch company said it is shuttering that Phase 3 trial. The setback overshadowed a separate win in celiac disease that Argenx reported the same day. Argenx shares tumbled on the news, reflecting how much of the company's valuation rests on extending Vyvgart beyond its approved uses.

Why it matters：The failure tests how far one of biotech's biggest autoimmune franchises can be extended, and the surprise futility call is a reminder that label-expansion bets carry binary risk for pipeline-dependent valuations.

Key points

  • A monitoring board recommended stopping the Sjögren's Phase 3 trial for futility.
  • Argenx is shuttering the trial; shares fell on the news.
  • The company also reported a win in celiac disease the same day.

Sources (original reporting)

More stories from this day